Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch
The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly in the obesity drug space.
TL;DR
- Novo Nordisk's new obesity pill, Wegovy, experienced an encouraging start in its U.S. launch, leading to an 8% rise in share price.
- Early prescription data suggests Wegovy's launch is strong, with some analysts calling it a 'solid start' and noting it may be outstripping injectable counterparts at the same stage.
- Analysts from TD Cowen and Leerink Partners are cautiously optimistic, emphasizing the need for more data to assess long-term demand and trends.
- Eli Lilly's competing obesity injection, Zepbound, had approximately 1,300 prescriptions filled in its first week and 8,000 in its second, compared to Wegovy's initial figures.
- The full impact of the launch and market share dynamics will become clearer over the next two to three quarters, with the upcoming launch of Eli Lilly's oral drug also a factor.
- Novo Nordisk's pill has dietary restrictions, while Eli Lilly's upcoming oral drug does not, which could influence future uptake.